AKT1 and malignant colon neoplasm: Strikingly, siRNA knockdown of CDC37 not only inhibited rebound activation of Akt in mutant BRAF colon cancer cells after treatment with AUY922, but also reduced the basal levels of activation of Akt in these cells (Figure 5B).